These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32009296)

  • 41. Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
    Giugliano D; De Nicola L; Maiorino MI; Bellastella G; Esposito K
    Diabetes Obes Metab; 2019 Aug; 21(8):1790-1800. PubMed ID: 30969018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors.
    Stonehouse A; Okerson T; Kendall D; Maggs D
    Curr Diabetes Rev; 2008 May; 4(2):101-9. PubMed ID: 18473757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?
    Davies MJ; Bianchi C; Del Prato S
    Metabolism; 2020 Jun; 107():154242. PubMed ID: 32315698
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular Effects of Incretin-Based Therapies.
    White WB; Baker WL
    Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Rationale supporting basal insulin-incretin combined therapies in type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Liege; 2013 Nov; 68(11):562-8. PubMed ID: 24396969
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implications of incretin-based therapies on cardiovascular disease.
    Rotz ME; Ganetsky VS; Sen S; Thomas TF
    Int J Clin Pract; 2015 May; 69(5):531-49. PubMed ID: 25363540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incretin-based treatment of diabetes and cardiovascular complications.
    Haluzík M
    Vnitr Lek; 2020; 66(2):74-80. PubMed ID: 32942880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Koska J; Sands M; Burciu C; Reaven P
    Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incretin-mimetic therapies and pancreatic disease: a review of observational data.
    Suarez EA; Koro CE; Christian JB; Spector AD; Araujo AB; Abraham S
    Curr Med Res Opin; 2014 Dec; 30(12):2471-81. PubMed ID: 25180611
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.
    Wu S; Gao L; Cipriani A; Huang Y; Yang Z; Yang J; Yu S; Zhang Y; Chai S; Zhang Z; Sun F; Zhan S
    Diabetes Obes Metab; 2019 Apr; 21(4):975-983. PubMed ID: 30536884
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis.
    Pinto LC; Rados DV; Remonti LR; Viana LV; Pulz GT; Carpena MP; Borges RP; Marobin R; Beretta MV; Pedrollo EF; Londero TM; Machry R; Janeczko L; Moehlecke M; Falcetta MR; Bauer AC; Silveiro SP; Gerchman F; Rodrigues TC; Kramer CK; Bertoluci MC; Leitão CB
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32797182
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis.
    Chou CY; Chang YT; Yang JL; Wang JY; Lee TE; Wang RY; Hung CC
    Sci Rep; 2017 Nov; 7(1):15795. PubMed ID: 29150631
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular protective properties of incretin-based therapies in type 2 diabetes.
    Simsek S; de Galan BE
    Curr Opin Lipidol; 2012 Dec; 23(6):540-7. PubMed ID: 23160401
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
    Dejager S; Schweizer A
    Hosp Pract (1995); 2012 Apr; 40(2):7-21. PubMed ID: 22615074
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond.
    Viljoen A; Bain SC
    Endocrinol Metab (Seoul); 2023 Feb; 38(1):25-33. PubMed ID: 36740965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Diabetes Medications Targeting the Incretin System on the Kidney.
    MacIsaac RJ; Thomas MC
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):321-323. PubMed ID: 29321176
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
    Mathieu C; Bollaerts K
    Int J Clin Pract Suppl; 2007 Aug; (154):29-37. PubMed ID: 17593275
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.